US Federal Circuit Swats Attempt To Block Sandoz’s Pirfenidone
Six-Patent Non-Infringement Decision Appealed By Originator Genentech
Sandoz won big earlier this year at the district court level following its submission of ANDAs referencing Genentech’s Esbriet (pirfenidone) treatments for idiopathic pulmonary fibrosis. The Roche subsidiary has failed in its attempts to secure an injunction pending appeal, while firing off on the district court for its earlier ruling.
